InterCure (INCR) Competitors $1.33 -0.05 (-3.61%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends INCR vs. BNTC, PYXS, ACB, TRVI, BMEA, TCRX, STRO, CYBN, MOLN, and MGNXShould you be buying InterCure stock or one of its competitors? The main competitors of InterCure include Benitec Biopharma (BNTC), Pyxis Oncology (PYXS), Aurora Cannabis (ACB), Trevi Therapeutics (TRVI), Biomea Fusion (BMEA), TScan Therapeutics (TCRX), Sutro Biopharma (STRO), Cybin (CYBN), Molecular Partners (MOLN), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical products" industry. InterCure vs. Benitec Biopharma Pyxis Oncology Aurora Cannabis Trevi Therapeutics Biomea Fusion TScan Therapeutics Sutro Biopharma Cybin Molecular Partners MacroGenics InterCure (NASDAQ:INCR) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, community ranking, media sentiment and valuation. Does the media prefer INCR or BNTC? In the previous week, Benitec Biopharma had 5 more articles in the media than InterCure. MarketBeat recorded 6 mentions for Benitec Biopharma and 1 mentions for InterCure. InterCure's average media sentiment score of 1.93 beat Benitec Biopharma's score of 1.18 indicating that InterCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InterCure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Benitec Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of INCR or BNTC? 8.3% of InterCure shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 0.2% of InterCure shares are held by company insiders. Comparatively, 1.3% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has higher earnings and valuation, INCR or BNTC? InterCure has higher revenue and earnings than Benitec Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInterCure$96.61M0.63-$16.83MN/AN/ABenitec Biopharma$80K3,094.07-$21.75MN/AN/A Which has more volatility & risk, INCR or BNTC? InterCure has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Does the MarketBeat Community believe in INCR or BNTC? Benitec Biopharma received 186 more outperform votes than InterCure when rated by MarketBeat users. However, 100.00% of users gave InterCure an outperform vote while only 64.73% of users gave Benitec Biopharma an outperform vote. CompanyUnderperformOutperformInterCureOutperform Votes3100.00% Underperform VotesNo VotesBenitec BiopharmaOutperform Votes18964.73% Underperform Votes10335.27% Do analysts recommend INCR or BNTC? Benitec Biopharma has a consensus price target of $22.60, indicating a potential upside of 112.01%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Benitec Biopharma is more favorable than InterCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Benitec Biopharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Is INCR or BNTC more profitable? InterCure's return on equity of 0.00% beat Benitec Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets InterCureN/A N/A N/A Benitec Biopharma N/A -60.28%-53.02% SummaryBenitec Biopharma beats InterCure on 9 of the 16 factors compared between the two stocks. Ad Angel PublishingTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. Get InterCure News Delivered to You Automatically Sign up to receive the latest news and ratings for INCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCR vs. The Competition Export to ExcelMetricInterCurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.89M$6.41B$5.01B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E RatioN/A10.57134.3717.77Price / Sales0.63243.641,158.6875.18Price / CashN/A22.1633.5332.53Price / Book0.495.474.674.68Net Income-$16.83M$153.61M$119.07M$226.08M7 Day Performance6.71%-2.00%-1.83%-1.04%1 Month Performance-22.90%-7.47%-3.62%1.04%1 Year Performance15.99%31.80%31.63%26.28% InterCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCRInterCure1.2491 of 5 stars$1.33-3.6%N/A+16.0%$62.89M$96.61M0.00350Positive NewsBNTCBenitec Biopharma2.2948 of 5 stars$10.66+7.9%$22.60+112.0%+202.8%$247.53M$80,000.000.0020Positive NewsPYXSPyxis Oncology1.0428 of 5 stars$3.82-8.2%$9.57+150.6%+165.3%$247.38MN/A0.0060News CoverageGap UpHigh Trading VolumeACBAurora Cannabis0.6391 of 5 stars$4.24+1.4%N/A-11.0%$232.52M$200.35M-5.581,073TRVITrevi Therapeutics3.4144 of 5 stars$2.77-7.7%$7.43+168.2%+113.1%$230.60MN/A0.0020BMEABiomea Fusion3.4346 of 5 stars$6.28-2.2%$30.50+385.7%-39.1%$227.58MN/A-1.5750TCRXTScan Therapeutics2.6162 of 5 stars$4.12-2.1%$12.00+191.3%-10.6%$223.02M$21.05M0.00100STROSutro Biopharma4.5351 of 5 stars$2.67-1.1%$12.14+354.8%-3.6%$222.64M$153.73M0.00240Analyst ForecastAnalyst RevisionCYBNCybin1.4673 of 5 stars$11.14+1.2%$138.00+1,139.3%N/A$222.59MN/A-1.6750Analyst ForecastGap UpMOLNMolecular Partners0.389 of 5 stars$5.20-4.8%$4.50-13.5%+19.8%$220.24M$7.84M0.00180MGNXMacroGenics3.8684 of 5 stars$3.28-5.7%$7.63+132.5%-57.0%$218.42M$58.75M0.00430 Related Companies and Tools Related Companies BNTC Competitors PYXS Competitors ACB Competitors TRVI Competitors BMEA Competitors TCRX Competitors STRO Competitors CYBN Competitors MOLN Competitors MGNX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INCR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InterCure Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share InterCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
